Dr. Sima Rozati is an Assistant Professor of Dermatology at the Johns Hopkins University School of Medicine. She specializes in medical dermatology, cutaneous lymphoma, and supportive oncodermatology. She received her medical degree from the Shahid Beheshti University of Medical Sciences in Tehran. After completing her internal medicine residency at the Cleveland Clinic, she completed a research fellowship and PhD in cutaneous lymphoma at the University Hospital of Zürich in Switzerland. She returned to the U.S. where she completed cutaneous lymphoma fellowship, under the mentorship of Dr. Youn Kim, followed by dermatology residency at Stanford University School of Medicine in California. In a multidisciplinary environment, Dr. Rozati aims to provide excellent care to patients with cutaneous lymphoma and cancer whom are experiencing cutaneous adverse events from targeted therapies, immune- and chemotherapies. Dr. Rozati’s research interest focuses on cutaneous lymphoma, understanding the biology of this heterogeneous group of malignancies by analyzing the mutational and epigenetic landscape. Her translational research efforts is directed to investigate novel targeted and immunotherapeutic for cutaneous T cell lymphoma. She is a member of different professional organizations, including the American Academy of Dermatology and Woman’s dermatologic Society. Dr. Rozati is rated as an Elite provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Localized Scleroderma.

Dr. Ronald Sweren is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous lymphoma/mycosis fungoides, phototherapy/ photopheresis and melanoma. Dr. Sweren also serves as director of the Phototherapy/Photopheresis Program in the Department of Dermatology. Dr. Sweren earned his M.D. from the University of Maryland School of Medicine. He completed his residency in dermatology at University of Maryland Medical Center and in pediatrics at Sinai Hospital of Baltimore. Dr. Sweren is rated as a Distinguished provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Melanoma, and T-Cell Lymphoma.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Howard Hines is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include dermatology, melanoma and psoriasis. He received his B.A. in biology from Western Maryland College and his M.D. from the University of Maryland School of Medicine. He completed his residency in general internal medicine at Washington Hospital Center and performed a fellowship in dermatology at George Washington University Hospital. Dr. Hines is a member of several professional organizations, including the American Medical Association, American College of Physicians and American Society of Internal Medicine. CV http://www.hopkinsmedicine.org/dermatology/our_experts/_documents/Howard_C_Hines_Curriculum_vitae.doc Selected Publications Boudreau S, Hines HC, Hood AF. “Dermal abscess with staphylococcus aureus, cytomegalovirus, and acid-fast bacilli in a patient with acquired immunodeficiency syndrome.” Journal of Cutaneous Pathology. 1988;15:53-57. Horn TD, Hines HC. “Erythrophagocytosis in the skin: case report.” Journal of Cutaneous Pathology. 1988;15:399-403. Jawitz JC, Hines HC. “Treatment of eczema herpeticum with systemic acyclovir.” Archives of Dermatology. February 1985;121:274-275. Dr. Hines is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Pigmented Purpuric Dermatosis, Actinic Keratosis, Liver Spots, and Universal Acquired Melanosis.

Dr. Jaroslaw Jedrych is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include dermatopathology and anatomic pathology. Dr. Jedrych received his M.D. from the Warsaw Medical University. He completed his residency in anatomic pathology at Yale School of Medicine, where he served as chief resident. He then completed his fellowship in oncologic pathology at Memorial Sloan Kettering Cancer Center, where he served as chief fellow, and a dermatopathology fellowship at University of Pittsburgh Medical Center. Dr. Jedrych is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Epidermodysplasia Verruciformis, Trichoepithelioma, Warts, and Grover's Disease.

Dr. Jihad Mohamad Alhariri is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include dermatology and medical dermatology. Dr. Alhariri received his undergraduate degree from the American University of Beirut. He earned his M.D. from the American University of Beirut and his M.P.H. from the Johns Hopkins University School of Public Health. He completed a residency in internal medicine at Good Samaritan Hospital of Maryland and a residency in dermatology at Johns Hopkins. Dr. Alhariri is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Melanoma, Hidradenitis Suppurativa, Giant Congenital Melanocytic Nevus, and Giant Congenital Nevus.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Dr. Alexander J. Ambinder is an instructor of medicine at the Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins. Dr. Ambinder has expertise in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and bone marrow transplantation. Dr. Ambinder received his B.A. from Washington University in St. Louis. He earned his M.D. from Emory University School of Medicine and his M.P.H. from Emory University Rollins School of Public Health. He completed the Osler Medical Residency Training Program in internal medicine at Johns Hopkins and subsequently served as an Assistant Chief of Service (Chief Resident). He completed his fellowships in Hematology and Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and also served as a Chief Fellow. Dr. Ambinder is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Ambinder’s principle research interest is in designing and conducting clinical trials inspired by laboratory insights to improve the management of acute myeloid leukemia and myelodysplastic syndrome. He also has an interest in building large databases that will yield insights that allow for more personalized approaches to the care and treatment of patients with blood cancers. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Sterling is an oncologist who cares for patients with hematologic malignancies at the Johns Hopkins University School of Medicine. He is an active clinician with expertise in lymphoma and bone marrow transplantation and serves as the Director of the Johns Hopkins Lymphoma and Myeloma Multidisciplinary Conference. Dr. Sterling earned his undergraduate degree in biomedical sciences from Auburn University and his medical degree from Johns Hopkins University. He completed his training in internal medicine and medical oncology at Johns Hopkins before being recruited to the faculty. As a clinical investigator, Dr. Sterling's research focuses on the development of new technologies, therapies, and treatment strategies for lymphoma and other conditions treated with bone marrow transplantation. Dr. Sterling is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Peripheral T-Cell Lymphoma.

Edward Lee, M.D. was named one of Baltimore’s “Top Doc’s” by Baltimore Magazine in 2000 and 2002. After receiving additional training in Hematology and Medical Oncology at the University of Maryland in 1984, he remained on faculty until 1997. During his academic career, Dr. Lee was chairman of the training program for five years, started the Bone Marrow Transplant Program at the University of Maryland in 1993, and wrote 50 original articles on leukemia, lymphoma and related diseases. In 1997, Dr. Lee entered private practice as Chief of Hematology and Medical Oncology at Sinai Hospital. Practicing in Columbia since 2001, Dr. Lee treats patients with all forms of cancer, maintaining a particular interest in breast cancer, leukemia, and lymphomas. Learn more at marylandoncology.com. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Polycythemia Vera, Paget Disease of the Breast, Breast Cancer, and Primary Lymphoma of the Brain.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Leukemia, and Splenectomy.

Courtney Johnson is a Dermatologist in Lutherville, Maryland. Dr. Johnson is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). Her top areas of expertise are Mycosis Fungoides, Melanoma, Cutaneous T-Cell Lymphoma (CTCL), and Giant Congenital Melanocytic Nevus.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

Luette Semmes is a Dermatologist in Salisbury, Maryland. Dr. Semmes is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). Her top areas of expertise are Actinic Keratosis, Warts, Seborrheic Keratosis, and Plaque Psoriasis. Dr. Semmes is currently accepting new patients.

Richard Piekarz is an Oncologist in Bethesda, Maryland. Dr. Piekarz is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, and Non-Hodgkin Lymphoma.

Shawn Kwatra is a Dermatologist in Baltimore, Maryland. Dr. Kwatra is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Prurigo Nodularis, Atopic Dermatitis, Lichen Simplex Chronicus, and Psoriasis. Dr. Kwatra is currently accepting new patients.

Roisin Connolly is an Oncologist in Baltimore, Maryland. Dr. Connolly is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Tissue Biopsy.

Wyndham Wilson is an Oncologist in Bethesda, Maryland. Dr. Wilson is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Burkitt Lymphoma.

Maren Shaw is a Dermatologist in White Plains, Maryland. Dr. Shaw is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). Her top areas of expertise are Keloids, Sunburn, Actinic Keratosis, and Rosacea. Dr. Shaw is currently accepting new patients.